~~<i id='895954943D'><strike id='895954943D'><tt id='895954943D'><pre id='895954943D'></pre></tt></strike></i>~~

Home» Wikipedia» entertainment

entertainment

author：comprehensive 2025-09-27 20:38:14 Page View：796

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Would Medicare drug price negotiations stall in a shutdown?
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

explore

ChatGPT in medicine: STAT answers readers' burning questions

MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

NIH fellows want a pay raise. Will that mean less money for grants?

NIHresearchfellowswanttounionize,inlargepartbecausetheywantaraise.Willthatmeanlessmoneyforgrants?Lyd

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Paxlovid should be available without a positive Covid test

JoeRaedle/GettyImagesThepandemicisoverformostoftheworld.Butforthe2.7%ofadultsintheUnitedStateswhoare